Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection. The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-alpha, and interleukin-beta concentrations in BALF were lower in the anti-PcrV IgG-treated groups when compared with controls. Plasma anti-PcrV IgG titre was elevated after administration of anti-PcrV IgG. Although plasma titre decreased gradually, a significant concentration was maintained during the experimental period. These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.
Imamura
Y
Y
Second Dept of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Yanagihara
K
K
Fukuda
Y
Y
Kaneko
Y
Y
Seki
M
M
Izumikawa
K
K
Miyazaki
Y
Y
Hirakata
Y
Y
Sawa
T
T
Wiener-Kronish
J P
JP
Kohno
S
S
D000818:Animals; D000907:Antibodies, Bacterial / Q000378:metabolism / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000276:immunology*; D001427:Bacterial Toxins / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D051379:Mice; D052899:Pore Forming Cytotoxic Proteins; D011552:Pseudomonas Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology / Q000472:pathogenicity*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D052899:Pore Forming Cytotoxic Proteins; C118546:antigen V, Pseudomonas